Autoimmune Diseases Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2028

Autoimmune Disease Diagnostics Market By Product (Reagents & Kits And Instruments), Disease Type (Localized Autoimmune Disease, And Systemic Autoimmune Disease), Test (Antinuclear Antibody Test, Autoantibody Test, Complete Blood Count, Comprehensive Metabolic Panel, C-Reaction Protein, Erythrocyte Sedimentation Rate, And Urinalysis), By End-User (Hospitals & Clinics, Diagnostics Centers, And Others) and geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of key diseases such as autoimmune disorders such as rheumatoid arthritis, diabetes, and multiple sclerosis.

The global Autoimmune Disease Diagnostics Market is estimated to grow at a CAGR of 5.53% during the forecast period from 2023 to 2028 to reach USD 6.41 billion by 2028. The demand for diagnosis of autoimmune diseases is primarily being boosted by the increasing number of cases of autoimmune disorders such as Rheumatoid Arthritis, Type I Diabetes, and Addison's Disease among others. Additionally, the rising awareness among people regarding early disease diagnosis and the rising technological advancement in the healthcare domain, are also contributing to the growth of the Autoimmune Diagnostics Market during the forecast period from 2023-2028.

Autoimmune Disease Diagnostics Market Dynamics:

As per the data published by Multiple Sclerosis International Federation in 2020, the number of people suffering from multiple sclerosis has increased from 2.3 million in 2013 to 2.8 billion in 2020, globally. Furthermore, according to statistics provided by the World Health Organization (WHO) in the year 2023, around 18 million individuals worldwide suffered from rheumatoid arthritis in 2019. According to the same source, around 70% of persons suffering from rheumatoid arthritis in 2019 were women, with 55% being over the age of 55. Thus the rising prevalence of autoimmune disorders will create a need for diagnosis of autoimmune disorders, thus resulting in the positive growth of the Autoimmune Disease Diagnostic Market.

Another driver for the Autoimmune Disease Diagnostics market is growing public awareness about early disease detection. For example, the Autoimmune Association recognizes Autoimmune Disease Awareness Month every March. The primary goal of the awareness campaign is to raise public knowledge and comprehension of autoimmune illnesses. Thus, increased disease awareness causes a requirement for early diagnosis of the ailments, which plays a critical role in driving the Autoimmune Disease Diagnostics Market.

However, the high cost of diagnosing autoimmune illnesses, as well as the long turnaround time and the requirement of many tests, are some of the key constraints that may limit the growth of the autoimmune disease diagnostic market.

Autoimmune Disease Diagnostics Market Segment Analysis:

Autoimmune Disease Diagnostics Market by Product (Reagents & Kits and Instruments), Disease type (Localized Autoimmune Disease and Systemic Autoimmune Disease), Test (Antinuclear Antibody Test, Autoantibody Test, Complete Blood Count, Comprehensive Metabolic Panel, C-reaction Protein, Erythrocyte Sedimentation Rate, and Urinalysis), End-users (Hospitals & Clinics, Diagnostic Centers, and Others) and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

The Reagents & Kits category is estimated to account for a considerable revenue share in the Autoimmune Disease Diagnostics Market in 2022. This might be linked to the increased demand and consumption of kits and reagents, as well as the increasing number of tests done, as a result of the growing incidence of autoimmune illnesses worldwide. Furthermore, many benefits given by kits, including high sensitivity and excellent specificity, are some of the reasons contributing to the segment's rise.

Furthermore, the kits and reagents are required for every test, making them an essential element of the testing procedure during the illness diagnostic process.

Furthermore, as the demand for this segment grows, novel products are being approved by various regulatory agencies. For example, in June 2021, Inova Diagnostics, a global pioneer in the development of in-vitro diagnostic reagents and systems for autoimmune illnesses, gained FDA 510(k) clearance in the United States for its Aptiva® Celiac Disease IgA test.

As a result of the aforementioned factors, the reagents and kits segment is expected to grow significantly during the forecast period, consequently driving the expansion of the overall Autoimmune Disease Diagnostics Market.

North America is expected to dominate the overall Autoimmune Disease Diagnostics Market:

North America is expected to account for the highest proportion of the Autoimmune Disease Diagnostics Market in 2022, out of all regions. This is due to the existence of a significant patient pool in the region suffering from autoimmune illness. Furthermore, increased consumer awareness of illness diagnosis, support from the government, and a highly viable market in terms of product development and launches are some of the factors driving the growth of the Autoimmune Disease Diagnostics Market in North America.

According to statistics given by the Centers for Disease Control and Prevention (CDC) in 2023, it was estimated that around 21.2% of people (53.2 million) in the United States were diagnosed with arthritis between 2019 and 2021.

Further, according to the data provided by Multiple Sclerosis Canada 2020, over 90,000 people live with Multiple Sclerosis in Canada every year on average, which accounts for 1 in every 400 individuals. Thus according to the above-mentioned facts, this indicates a huge need for early diagnosis for the detection of autoimmune disorders therefore leading to the growth of the Autoimmune Disease Diagnostics market in North America.

Thus, the factors mentioned above, are thereby responsible for driving the North America Autoimmune Disease Diagnostics Market forward during the forecast period.

Autoimmune Disease Diagnostics Market Key Players:

Some of the key market players operating in the Autoimmune Disease Diagnostics Market include Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, Werfen, Bio-Rad Laboratories, Exagen Inc., Grifols, S.A, Medical & Biological Laboratories Co. Ltd, RSR Limited, DiaSorin S.p.A, Laboratory Corporation of America Holdings, Abcam plc, EUROIMMUN Medizinische Labordiagnostika AG, Quest Diagnostics, Hemagen Diagnostics, Inc., AESKU Diagnostics GmbH & Co. KG, Trinity Biotech and Biomerieux SA.

Recent Developmental Activities in the Autoimmune Disease Diagnostics Market:

• In October 2022, Sebia, a global specialty diagnostic company engaged in providing innovative solutions for screening and diagnosis of oncological, metabolic, genetic, and autoimmune disorders, acquired ZEUS Scientific.
• In May 2022, Thermofisher Scientific launched The new Phadia 2500+ series in the US, for the diagnosis of autoimmune disorders.
• In November 2020, Exagen and GSK partnered for 4th time consecutively, to create awareness of challenges facing lupus diagnosis and management.

Key Takeaways from the Autoimmune Disease Diagnostics Market Report Study

• Market size analysis for current Autoimmune Disease Diagnostics Market size (2022), and market forecast for 5 years (2023-2028)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Autoimmune Disease Diagnostics market.
• Various opportunities available for the other competitor in the Autoimmune Disease Diagnostics Market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028?
• Which are the top-performing regions and countries in the current Autoimmune Disease Diagnostics Market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Autoimmune Disease Diagnostics Market growth in the coming future?

Target Audience who can be benefited from this Autoimmune Disease Diagnostics Market Report Study

• Autoimmune Disease Diagnostics product providers
• Research organizations and consulting companies
• Autoimmune Disease Diagnostics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Autoimmune Disease Diagnostics
• Various End-users who want to know more about the Autoimmune Disease Diagnostics Market and the latest technological developments in the Autoimmune Disease Diagnostics Market.

Frequently Asked Questions for the Autoimmune Disease Diagnosis Market:

1. What is meant by Autoimmune Disorder?

Autoimmune Disorder is a condition in which the immune system mistakenly targets and attacks healthy cells, tissues, and organs in the body. This immune dysfunction can lead to inflammation and damage to the body tissues.

2. What is the market for global Autoimmune Disease Diagnostics?

The global Autoimmune Disease Diagnostics Market is estimated to grow at a CAGR of 5.53% during the forecast period from 2023 to 2028 to reach USD 6.41 billion by 2028.

3. What are the drivers for the global Autoimmune Disease Diagnostics market?

The Autoimmune Disease Diagnostics Market is slated to witness prosperity owing to factors such as the growing prevalence of autoimmune disorders such as Rheumatoid Arthritis, Type I Diabetes, and Multiple Sclerosis, among others. Additionally, growing awareness regarding early disease diagnosis and increasing research activities in the domain of autoimmune disease, are expected to result in appreciable revenue growth in the Autoimmune Disease Diagnostics Market during the forecast period (2023-2028).

4. Who are the key players operating in the global autoimmune disease diagnostics market?

Some of the key market players operating in the Autoimmune Disease Diagnostics Market include Beckman Coulter, Inc., Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermofisher Scientific, Werfen, Bio-Rad Laboratories, Exagen Inc., Grifols, S.A, Medical & Biological Laboratories Co. Ltd., RSR Limited, DiaSorin S.p.A, Laboratory Corporation of America Holdings, Abcam plc, EUROIMMUN Medizinische Labordiagnostika AG, Quest Diagnostics, Hemagen Diagnostics, Inc., AESKU Diagnostics GmbH & Co. KG, Trinity Biotech and Biomerieux SA.

5. Which region has the highest share in the global Autoimmune Disease Diagnostics market?

North America is expected to dominate the overall Autoimmune Disease Diagnostics Market during the forecast period, 2023 to 2028. This can be attributed to the presence of a large patient pool suffering from autoimmune disorders. Additionally, high consumer awareness regarding new market launches, government support, a highly potent market in terms of product development and launches, and the local presence of key market players are some of the factors influencing the positive growth of the market in the region during the forecast period.


This product will be delivered within 3-5 business days.